MGTA is a biotech ipo with Ph2 data due in H2/18 and a substantial cash runway. Technology involves bone marrow transplant using gene modified stem cells. MGTA intends to use this technology to target the following conditions: * Blood cancers * Myelodisplastic syndromes * Sickle Cell Disease * beta-Thalessemia * M.S. * Scleraderma The Ph2 data will be a clinical POC study for blood disorders. After the IPO, MGTA will have a cash runway of greater than 5 years at the present burn rate.